On the stock market since 2014, it operates in the world of health and science. It has 79 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 10% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $14.8M would still be left in the vault — a solid cushion for hard times.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 86% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 73% — still a thick cushion, though costs have been eating into it lately.
There is $14.9M in the vault; even if every debt were paid off, $14.8M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 3 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, SMLR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SMLR is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.